Evidence map›Paper›PMID 29607531›Full record

ArticleBritish journal of clinical pharmacology2018

Vancomycin-induced acute kidney injury in elderly Chinese patients: a single-centre cross-sectional study.

Kun-Ming Pan, Yi Wu, Can Chen, Zhang-Zhang Chen, Jian-An Xu, Lei Cao, Qing Xu, Wei Wu, Pei-Fang Dai, Xiao-Yu Li and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in British journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Kun-Ming PanDepartment of Pharmacy, Zhongshan Hospital FuDan University, Shanghai, China.ORCID 0000-0002-9213-123X
Yi WuDepartment of Pharmacy, Zhongshan Hospital FuDan University, Shanghai, China.
Can ChenDepartment of Pharmacy, Zhongshan Hospital FuDan University, Shanghai, China.
Zhang-Zhang ChenDepartment of Pharmacy, Zhongshan Hospital FuDan University, Shanghai, China.
Jian-An XuDepartment of Pharmacy, Zhongshan Hospital FuDan University, Shanghai, China.
Lei CaoDepartment of Pharmacy, Zhongshan Hospital FuDan University, Shanghai, China.
Qing XuDepartment of Pharmacy, Zhongshan Hospital FuDan University, Shanghai, China.
Wei WuDepartment of Pharmacy, Zhongshan Hospital FuDan University, Shanghai, China.
Pei-Fang DaiDepartment of Pharmacy, Zhongshan Hospital FuDan University, Shanghai, China.
Xiao-Yu LiDepartment of Pharmacy, Zhongshan Hospital FuDan University, Shanghai, China.
Qian-Zhou LvDepartment of Pharmacy, Zhongshan Hospital FuDan University, Shanghai, China.
Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe objective of the present study was to investigate the current situation concerning, and risk factors for, vancomycin (VAN)-induced acute kidney injury (VI-AKI) in elderly Chinese patients, to assess outcomes and risk factors in patients who have developed VI-AKI, in order to provide suggestions for improving the prevention and treatment of this condition in these patients.

methodWe retrospectively identified elderly older inpatients who had received four or more doses of VAN treatment. We compared patients with VI-AKI with those who received VAN treatment and had not developed AKI (NO-AKI). We defined VI-AKI as developing AKI during VAN therapy or within 3 days after withdrawal of VAN.

resultsA total of 647 out of 862 elderly inpatients were included in the study. Among those excluded, in 89.3% of cases (192/215) this was because of lack of data on serum creatinine (SCr). Among included patients, 32.5% (210/647) of patients received therapeutic drug monitoring (TDM) during VAN therapy. In 66.9% of cases (424/634), there was insufficient TDM, and in 3.9% (25/634) this was appropriate. A total of 102 patients had confirmed VI-AKI, with an incidence of 15.8% (102/647). Multiple logistic regression analysis revealed that hyperuricaemia [odds ratio (OR) = 3.045; P = 0.000)], mechanical ventilation (OR = 1.906; P = 0.022) and concomitant vasopressor therapy (OR = 1.919; P = 0.027) were independent risk factors for VI-AKI; higher serum albumin (OR = 0.885; P = 0.000) was determined to be an independent protective factor for VI-AKI.

conclusionsFor the elderly Chinese patients treated with VAN, there was insufficient monitoring of SCr, too little use of VAN TDM, and lower rate of patients whose VAN though serum concentrations were not obtained at the correct time. We recommend that hospital managers increase investment in clinical pharmacists, to strengthen professional management. Patients with concomitant hyperuricaemia and on mechanical ventilation and vasopressor therapy should be paid more attention, and a higher serum albumin was determined to be an independent protective factor for VI-AKI.

Indexed as

Acute Kidney InjuryAgedAged, 80 and overAge FactorsAnti-Bacterial AgentsChinaCross-Sectional StudiesDrug MonitoringFemaleHospitalizationHumansHyperuricemiaIncidenceKidneyMaleMethicillin-Resistant Staphylococcus aureusAnti-Bacterial AgentsVancomycinVasoconstrictor Agentsacute kidney injuryolder patientsrisk factorsvancomycin

Identifiers

PMID29607531
PMCPMC6046479
OpenAlexW2796164635

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.